Back to top

Analyst Blog

Apricus Biosciences, Inc. (APRI - Snapshot Report) recently announced that its erectile dysfunction (ED) drug, Vitaros, has been approved under the European Decentralized Procedure (DCP).

Apricus, along with its commercialization partners, Sandoz, Takeda Pharmaceutical (TKPYY) and Bracco, will now look to obtain national phase approvals to make Vitaros available in all territories across Europe.

Results from a phase III study evaluating the safety and efficacy of Vitaros and its long-term use in men who did not respond to phosphodiesterase type 5 (PDE-5) inhibitors like Viagra (n=325) showed that multiple doses of Vitaros (200 mcg and 300 mcg) improved erections in patients.

Apricus’ marketing approval application for Vitaros designated Netherlands as the Reference Member State (RMS) on behalf of nine other European Concerned Member States (France, Germany, Italy, UK, Ireland, Spain, Sweden, Belgium and Luxembourg) who participated in the procedure.

Although Apricus believes that Vitaros has the potential to capture a good share of the PDE-5 inhibitor market (worth approximately $1 billion) once launched, we note that the market currently has big companies like Eli Lilly and Company (LLY - Analyst Report).

The company also mentioned that it will continue to seek additional partnership agreements for Vitaros in the rest of the European and global markets.

Apricus was recently engaged in a $17.1 million financing. It also divested multiple non-core assets and has also streamlined its global operations. This should allow the company to focus on its lead assets for male and female sexual health, namely, Vitaros and Femprox.

Apricus presently carries a Zacks Rank #4 (Sell). Currently, companies like Jazz Pharmaceuticals (JAZZ - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%